This application seeks to support the career development of Dr John H. Stewart, IV. His long-term goal is to attain the necessary skills to become a well-trained clinician-scientist with a focus in the treatment of metastatic colorectal cancer and eventually become competitive for independent funding support. This goal will be met by a structured career development plan as well as a well-designed research project. Dr. Stewart's career development strategy will involve continued engagement with his present mentoring committee and participation in a structured didactic course of study to fill gaps in his scientific background. Dr. Stewart will present his research findings at national meetings and publish his work in peer reviewed journals during the proposed career development period. In addition to the aforementioned career development plan, Dr. Stewart and his mentoring committee have devised a research project titled """"""""Oncolytic Vesicular Stomatitis Virus (VSV) for the Treatment of Colorectal Cancer"""""""". The overall hypothesis of this research project is that local delivery of oncolytic VSV can effectively treat properly selected, metastatic colorectal tumors of the liver and peritoneum. This hypothesis will be tested by three specific aims.
In Specific Aim 1, he will seek to identify the molecular determinants of host-cell permissiveness to VSV in colorectal cancer cells.
In Specific Aim 2 he will define the apoptotic pathways activated by VSV in colorectal cancer cells.
In Specific Aim 3 he will delineate the efficacy of loco-regional delivery of VSV in small animal models of metastatic colorectal cancer. The research proposed in this application will set the stage for further translational research by advancing the novel paradigm of local delivery of oncolytic VSV for the treatment of metastatic colorectal cancer. The Comprehensive Cancer Center of Wake Forest University provides an excellent environment for a mentored training program. This center incorporates expertise from a broad variety of disciplines and has extensive resources. Dr. Stewart has laboratory space that is fully funded by the Department of Surgery. He has the full support of his Division Chief to devote at least 75% of his time to the career development plan outlined in this proposal. Relevance: It is projected that 153,760 individuals will be diagnosed with colorectal cancer in 2007. Despite advances in early diagnosis, surgery and systemic therapy, an estimated 52,180 patients will die of metastatic disease this year. Clearly, new therapies are needed to treat advanced colorectal cancer. This project will attempt to address the need for novel treatments of metastatic colorectal cancer by exploring the efficacy of VSV in the treatment of this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA131482-04
Application #
8091348
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ojeifo, John O
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
4
Fiscal Year
2011
Total Cost
$146,367
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Surgery
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Blackham, Aaron U; Northrup, Scott A; Willingham, Mark et al. (2014) Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. J Surg Res 187:412-26
Randle, Reese W; Northrup, Scott A; Sirintrapun, S Joseph et al. (2013) Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. Surgery 154:1323-29; discussion 1329-30
Blackham, Aaron U; Northrup, Scott A; Willingham, Mark et al. (2013) Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery 153:333-43
Votanopoulos, Konstantinos I; Ihemelandu, Chukwuemeka; Shen, Perry et al. (2012) Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg 215:412-7
Duckworth, Katharine E; McQuellon, Richard P; Russell, Gregory B et al. (2012) Patient rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CSýýý+ýýýHIPEC). J Surg Oncol 106:376-80
Levine, Edward A; Blazer 3rd, Dan G; Kim, Mickey K et al. (2012) Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg 214:599-606; discussion 606-7
Stewart 4th, John H (2012) Transcriptional targeting of bone morphogenetic protein receptors: is it ready for prime time? J Surg Res 178:601-3
Howard-McNatt, Marissa; Geisinger, Kim R; Stewart 4th, John H et al. (2012) Is intraoperative imprint cytology evaluation still feasible for the evaluation of sentinel lymph nodes for lobular carcinoma of the breast? Ann Surg Oncol 19:929-34
Stewart 4th, John H; Shen, Perry; Russell, Greg et al. (2012) Erratum to: A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination from Colorectal and Appendiceal Cancers. Ann Surg Oncol 19:2421
Stewart 4th, J H; Ahmed, M; Northrup, S A et al. (2011) Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther 18:837-49

Showing the most recent 10 out of 29 publications